Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Novel low-pollution route for Oxibendazole using m-dichlorobenzene. Reduces cost and environmental impact for veterinary drug manufacturing.
Novel crystallization method for >99.5% purity guaiacol glycidyl ether. Reduces solvent use and equipment costs for ranolazine intermediates.
Patent CN105367535B reveals trisulfonic acid ionic liquid catalyst for high-purity acridine derivatives manufacturing with reduced waste and cost.
Novel one-pot method using elemental sulfur and DMF achieves 90% yield in 3 hours, offering significant cost reduction for pharmaceutical intermediate manufacturing.
Patent CN117658830B enables high-optical-purity trans-2-aminocyclopentanol synthesis. Safe resolution process offers supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN101831479B reveals a microbial method for synthesizing sulforaphane precursors, offering significant cost reduction and scalable production for pharmaceutical intermediates.
Patent CN107384885B reveals enzymatic synthesis of chiral amines. Achieve cost reduction in API manufacturing with high conversion and optical purity.
Patent CN103965118A details a novel synthesis of pinanyl-2-aminopyrimidine compounds from turpentine. This report analyzes technical feasibility and supply chain advantages for pharmaceutical manufacturers.
Patent CN1563014A details novel Garcinia acid derivatives with enhanced stability and solubility for oncology. Discover cost-effective manufacturing strategies for these high-purity pharmaceutical intermediates.
Patent CN1563014A details stable Garcinia acid derivatives with enhanced solubility and reduced toxicity, offering reliable supply for anticancer drug manufacturing.
Patent CN102351870B details a robust synthesis of benzacridine derivatives targeting c-myc DNA. This report analyzes cost-effective manufacturing and supply chain scalability.
Novel method for benzacridine derivatives targeting c-myc DNA offers scalable routes and cost-effective manufacturing for global pharmaceutical supply chains.
Patent CN101974604A reveals a green enzymatic route for paroxetine intermediates using ionic liquids, offering high purity and reduced environmental impact for API manufacturing.
Patent CN102276631A details an optimized route for Cefepime Hydrochloride using BSA protection and wet feeding, ensuring high purity and cost-effective manufacturing for global supply chains.
Patent CN111196770A reveals a novel 2-step route for Bromfenac Sodium, offering significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN1968927B details a novel Ru-catalyzed route for high-purity quinoline intermediates used in bronchodilators, offering significant cost reduction in API manufacturing.
Patent CN103755708B reveals mild Rh-catalyzed C-H activation for high-purity indole intermediates, offering cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN108329289B reveals a novel Pd-catalyzed route for isocoumarin drug intermediates. Achieve high purity and cost reduction in pharmaceutical manufacturing with scalable methods.
Patent CN103102379B details a high-purity epiandrosterone route eliminating hydrogenation. This offers substantial cost reduction in steroid manufacturing and supply chain reliability.
Patent CN108690100A reveals a novel acetyl-protection route for Fondaparinux sodium intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.